28th Pharmacovigilance 2022

28th Pharmacovigilance 2022

15th & 16th June 2022, Embassy Suites by Hilton Boston Logan Airport Boston, USA

DELEGATE REGISTRATION:

Email - [email protected] or TEL: +44-20 3509 3779

Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer.

Standard Pricing - 1 Delegate @ £1,599+20% VAT

For Group Discount, Conference Sponsor, Exhibition Stall & Paid Speaker Slot - Please email your interest and queries to [email protected]

KEY SPEAKERS:

• BRUNO MENDEZ, VP Global Quality Head Pharmacovigilance, Sanofi

• MARIETTE BOERSTOEL-STREEFLAND, SVP Patient Safety, Chief Safety Officer, Alexion Pharmaceuticals

• CARMIT STRAUSS, Global Benefit Risk Director, Global Patient Safety, Amgen

• KHAUDEJA BANO, Vice President, Combination Product Quality, Amgen

• BRIAN DREYFUS, Senior Director -Solid Tumor Oncology Epidemiology, Bristol-Myers Squibb

• ELENA YURENEVA, Executive Director, Head of Medical Safety and Risk Management, Alnylam Pharmaceuticals

• ANUPAM AGARWAL, Vice President, Global Head of Drug Safety and Pharmacovigilance, Zogenix

• NANCY DUBOIS, Associate Director, Local Safety Officer, US Region, Alexion Pharmaceuticals

• SHARON REID, Director, Risk Management Product Lead, Pfizer

• TEODORA DOHERTY, Global Medical Safety (GMS), Medical Safety Officer, Janssen Research & Development

• ANKA G. EHRHARDT, Director, Cell-Based Assays / Analytical Research & Development, Merck

• FATIMA GHETHAN, Head of Quality and Medic*tion Safety Department, King Abdullah Medical City (KAMC) – MAKKAH (Saudi Arabia)

• JAYLAXMI NALAWADE, Associate Director - Pharmacovigilance and REMS, Lupin

• DEEPA VENKATARAMAN, Head of Global Patient Safety and Pharmacovigilance, Summit Therapeutics

• KATARINA ILIC, Senior Clinical Pharmacology Medical Leader, Takeda Pharmaceuticals

• KAL ELHOREGY, Director, Risk Evaluation and Mitigation Strategy (REMS) Programs, Amneal Pharmaceuticals

• AYSE BAKER, Vice President of Regulatory Affairs, Almatica (Alvogen)

• SUTAPA MUKHOPADHYAY, Director, Pharmacovigilance Operations, Deciphera Pharmaceuticals

• KAPIL BHUTADA, Director, Pharmacovigilance Compliance and Training, Medicago

• SHAANTANU DONDE, Head of Portfolio Management Team - Medical Affairs, Viatris

• BILL HADDOCK, Head of Safety, Ovid Therapeutics

• RAJ LONG, Deputy Director - Safety & Pharmacovigilance, Gates Foundation

• MELVA T. COVINGTON, Senior VP, Research and Patient Outcomes, Curio Digital Therapeutics

• JERRY K. KOUNGA, Investigational Drug Lead Clinical Research Pharmacist, Ascension Wisconsin Research Institute

• BEN LOCWIN, Executive SME, Black Diamond Networks

• KERRI DRUMMOND, Associate Director, Safety Scientist, Sarepta Therapeutics

• JESSICA VAUGHN, Attorney at Law, Wiley Rein

• ELIZABETH WHITE BAKER, Associate Professor, Virginia Commonwealth University

Host or Publisher Virtue Insight